FORA Capital LLC Acquires 5,570 Shares of IQVIA Holdings Inc. $IQV

Key Points

• FORA Capital LLC has increased its holdings in IQVIA Holdings Inc. by 45%, now owning a total of 17,936 shares valued at approximately $3.16 million as reported in their recent SEC filing.
• Seventeen research analysts have rated IQVIA with a Buy rating, while the average price target is set at $228.62, indicating anticipated growth in the company's stock performance.
• IQVIA reported a quarterly earnings of $2.81 per share, beating estimates of $2.77, with revenues of $4.02 billion, which is an increase of 5.3% from the previous year.

FORA Capital LLC increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 45.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,936 shares of the medical research company's stock after buying an additional 5,570 shares during the period. FORA Capital LLC's holdings in IQVIA were worth $3,162,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. American National Bank & Trust bought a new position in shares of IQVIA in the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC boosted its stake in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares during the period. AllSquare Wealth Management LLC purchased a new position in IQVIA during the 1st quarter valued at about $33,000. Finally, ST Germain D J Co. Inc. increased its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the period. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on IQV. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Cowen reiterated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Truist Financial lifted their price objective on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Buying and Selling

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Trading Up 0.0%

Shares of IQV stock opened at $188.05 on Wednesday. The business has a 50-day moving average price of $174.96 and a two-hundred day moving average price of $167.97. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market cap of $31.97 billion, a P/E ratio of 27.21, a price-to-earnings-growth ratio of 2.06 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.